The story
In 1973 Stanley Cohen of Stanford University and Herbert Boyer of the University of California, San Francisco, with colleagues Annie Chang and Robert Helling, showed that a gene could be cut from one source, stitched into a small ring of DNA called a plasmid, and put into bacteria, which then copied it every time they divided. The result was recombinant DNA: genetic material recombined from different sources. Soon after, the team moved genes from a frog into bacteria, proving that DNA from very different organisms could work together in one cell.
Their method combined tools other scientists had found. The structure of DNA, revealed in 1953, explained how genes are stored as sequences of four chemical letters. In the late 1960s and early 1970s researchers discovered restriction enzymes, proteins that bacteria use to chop up invading viruses at specific letter sequences. Boyer's lab worked with one called EcoRI, which leaves short single-stranded 'sticky ends' that naturally pair up with matching ends, while another enzyme, DNA ligase, glues the pieces together. Cohen had plasmids that carried antibiotic resistance, which let researchers find the bacteria that had taken up the new DNA by simply adding the antibiotic. In 1972 Paul Berg at Stanford had joined DNA from two viruses but held back from putting it into bacteria because of safety concerns.
Those concerns grew. Scientists worried that engineered microbes might escape labs and cause disease. In 1974 researchers called for a voluntary pause on some experiments, and in February 1975 about 140 people met at Asilomar in California to draw up safety rules, an unusual case of scientists regulating their own field before governments did. The work resumed under guidelines from the U.S. National Institutes of Health.
Then came business. In 1976 Boyer and venture capitalist Robert Swanson founded Genentech, often called the first biotech company. By 1978 it had made bacteria produce human insulin, and in 1982 that insulin, sold as Humulin, became the first genetically engineered drug approved in the United States. Stanford and the University of California patented the Cohen and Boyer method and licensed it widely, and recombinant DNA became the basic toolkit of modern biology.
Why it mattered
- Diabetics gained human insulin made by bacteria in 1982, replacing insulin extracted from pig and cow pancreases.
- Molecular biology took off, enabling Sanger DNA sequencing, PCR and eventually CRISPR gene editing.
- Genetically modified crops reached farms, starting with engineered plants in the 1980s.
- Biotech medicines followed, including the HPV vaccine, checkpoint inhibitor cancer drugs and the GLP-1 drugs.
- Modified mRNA research built on decades of recombinant techniques, leading to the COVID-19 vaccines.
Sources
- DNA cloning: a personal view after 40 years PNAS
- Herbert W. Boyer and Stanley N. Cohen Science History Institute
- Stanley N. Cohen: Transforming Molecular Biology Lasker Foundation
- After Asilomar Center for Genetics and Society
- Biotech Pioneers: rDNA and Insulin National Science Foundation
Drafted by AI (Claude) from the sources above and checked against them by AI; no historian has reviewed this page. Spot a mistake? Suggest a correction. How pages are made
Community notes
Loading notes…